Overview
PLUR market data
Price History
PLUR price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.56 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.69 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10,911.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.45 – $5.68 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $17.9M · P/B 323.05 · P/S 99.62.
Company News
Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+Benzinga · Jul 28, 2026, 12:06 PM
8-K filing — Pluri Inc. (PLUR)SEC EDGAR · Jul 14, 2026, 8:01 PM
Pluri Announces Chairman Alejandro Weinstein Has Invested $17M+In PLUR, Including A $1.25M Advance Investment Made In June 2026Benzinga · Jul 14, 2026, 11:16 AM
Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial LaunchBenzinga · Jun 2, 2026, 11:38 AM